BR112012009846A2 - ensaios para detecção de anticorpos específicos para anticorpos anti-ige terapêuticos e seu uso em anafilaxia - Google Patents
ensaios para detecção de anticorpos específicos para anticorpos anti-ige terapêuticos e seu uso em anafilaxiaInfo
- Publication number
- BR112012009846A2 BR112012009846A2 BR112012009846A BR112012009846A BR112012009846A2 BR 112012009846 A2 BR112012009846 A2 BR 112012009846A2 BR 112012009846 A BR112012009846 A BR 112012009846A BR 112012009846 A BR112012009846 A BR 112012009846A BR 112012009846 A2 BR112012009846 A2 BR 112012009846A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- anaphylaxis
- therapeutic anti
- assays
- detection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25505209P | 2009-10-26 | 2009-10-26 | |
US61/255,052 | 2009-10-26 | ||
PCT/US2010/054160 WO2011056606A1 (en) | 2009-10-26 | 2010-10-26 | Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112012009846A2 true BR112012009846A2 (pt) | 2017-02-21 |
BR112012009846B1 BR112012009846B1 (pt) | 2021-04-20 |
BR112012009846B8 BR112012009846B8 (pt) | 2021-05-25 |
Family
ID=43970265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012009846A BR112012009846B8 (pt) | 2009-10-26 | 2010-10-26 | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige |
Country Status (19)
Country | Link |
---|---|
US (1) | US9315583B2 (pt) |
EP (1) | EP2494356B1 (pt) |
JP (1) | JP6139885B2 (pt) |
KR (1) | KR101832510B1 (pt) |
CN (1) | CN102695956B (pt) |
AU (1) | AU2010315470B2 (pt) |
BR (1) | BR112012009846B8 (pt) |
CA (1) | CA2778810C (pt) |
DK (1) | DK2494356T3 (pt) |
HK (1) | HK1175538A1 (pt) |
HU (1) | HUE033492T2 (pt) |
IL (1) | IL219337A (pt) |
MX (1) | MX344935B (pt) |
MY (1) | MY182750A (pt) |
NZ (1) | NZ599600A (pt) |
RU (1) | RU2642295C2 (pt) |
SI (1) | SI2494356T1 (pt) |
WO (1) | WO2011056606A1 (pt) |
ZA (1) | ZA201202999B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9846126B2 (en) | 2008-10-27 | 2017-12-19 | Genalyte, Inc. | Biosensors based on optical probing and sensing |
WO2013066986A1 (en) * | 2011-10-31 | 2013-05-10 | Puget Sound Blood Genter | Antibody response phenotyping |
AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
JP6571660B2 (ja) * | 2013-12-20 | 2019-09-04 | フアデイア・アー・ベー | 抗体の分析 |
TWI691512B (zh) | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Fc融合高親和性IgE受體α鏈 |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
KR101957411B1 (ko) | 2017-09-13 | 2019-03-12 | (주)뷰티화장품 | 생약 추출물 함포 펙틴 마이크로캡슐을 포함하는 피부 개선용 화장료 조성물 |
AU2019206205A1 (en) * | 2018-01-12 | 2020-06-25 | Gi Innovation, Inc. | Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof |
WO2019212993A1 (en) * | 2018-04-30 | 2019-11-07 | Genalyte, Inc. | Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics |
CN113474657A (zh) * | 2019-02-21 | 2021-10-01 | 丁勤学 | 使用微粒去除非特异性结合信号的方法 |
MX2022000285A (es) * | 2019-07-08 | 2022-02-03 | Gi Innovation Inc | Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo. |
CN112285351A (zh) * | 2019-07-22 | 2021-01-29 | 上海益诺思生物技术股份有限公司 | 一种抗IgE单抗的ELISA检测方法 |
CN110358738B (zh) * | 2019-08-22 | 2021-08-13 | 中国食品药品检定研究院 | 一种稳定测定抗IgE抗体药物生物学活性的方法 |
JP7062803B1 (ja) * | 2021-03-31 | 2022-05-06 | 積水メディカル株式会社 | 抗薬物抗体測定方法 |
CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
CN116699147A (zh) * | 2023-08-04 | 2023-09-05 | 军科正源(北京)药物研究有限责任公司 | 检测总IgE含量的方法以及相关试剂盒 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE337223B (pt) | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
GB1319315A (en) | 1969-06-19 | 1973-06-06 | Citizen Watch Co Ltd | Calendar timepiece |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4459359A (en) * | 1981-11-19 | 1984-07-10 | New York Blood Center, Inc. | Sensitive immunoassays of antigens or antibodies sequestered within immune complexes |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4683136A (en) * | 1985-03-06 | 1987-07-28 | Scripps Clinic And Research Foundation | Proteinaceous antigens with conformation-independent and conformation-dependent determinants |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992017207A1 (en) | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
JPH0772150A (ja) * | 1993-09-02 | 1995-03-17 | Tonen Corp | IgEの測定方法 |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
DE69840334D1 (de) * | 1997-09-22 | 2009-01-22 | Novartis Vaccines & Diagnostic | Puffern zur stabilizierung von hcv antigenen |
AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
EP1527099A2 (en) * | 2002-08-01 | 2005-05-04 | Northwestern University | Mutants of ige proteins and uses thereof |
ES2566778T3 (es) | 2003-02-01 | 2016-04-15 | Tanox, Inc. | Anticuerpos anti-IgE de humano de alta afinidad |
BRPI0403964B8 (pt) | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
ES2340767T5 (es) * | 2004-07-01 | 2013-11-13 | Biomay Ag | Alérgenos de ácaros del polvo doméstico |
JP2008515780A (ja) * | 2004-09-02 | 2008-05-15 | ジェネンテック・インコーポレーテッド | 抗FcγRIIBレセプター抗体およびその使用 |
DE602005015981D1 (de) * | 2005-10-17 | 2009-09-24 | Pls Design Gmbh | Chimäre zwischen einer alpha-Kette eines humanen IgE Rezeptor und konstanten Immunoglobulin-Domänen von Vögeln zur Determination von Serum IgE. |
US20070184501A1 (en) * | 2006-02-07 | 2007-08-09 | Beckman Coulter, Inc. | Blocker reagent for reduction of heterophile interferences |
WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
-
2010
- 2010-10-26 EP EP10828867.1A patent/EP2494356B1/en active Active
- 2010-10-26 DK DK10828867.1T patent/DK2494356T3/en active
- 2010-10-26 MX MX2012004833A patent/MX344935B/es active IP Right Grant
- 2010-10-26 AU AU2010315470A patent/AU2010315470B2/en active Active
- 2010-10-26 WO PCT/US2010/054160 patent/WO2011056606A1/en active Application Filing
- 2010-10-26 MY MYPI2012001843A patent/MY182750A/en unknown
- 2010-10-26 HU HUE10828867A patent/HUE033492T2/en unknown
- 2010-10-26 CA CA2778810A patent/CA2778810C/en active Active
- 2010-10-26 SI SI201031455A patent/SI2494356T1/sl unknown
- 2010-10-26 RU RU2012121559A patent/RU2642295C2/ru active
- 2010-10-26 KR KR1020127013539A patent/KR101832510B1/ko active IP Right Grant
- 2010-10-26 BR BR112012009846A patent/BR112012009846B8/pt active IP Right Grant
- 2010-10-26 CN CN201080059348.8A patent/CN102695956B/zh active Active
- 2010-10-26 US US12/912,657 patent/US9315583B2/en active Active
- 2010-10-26 NZ NZ59960010A patent/NZ599600A/en unknown
- 2010-10-26 JP JP2012536969A patent/JP6139885B2/ja active Active
-
2012
- 2012-04-22 IL IL219337A patent/IL219337A/en active IP Right Grant
- 2012-04-24 ZA ZA2012/02999A patent/ZA201202999B/en unknown
-
2013
- 2013-03-11 HK HK13102961.6A patent/HK1175538A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR101832510B1 (ko) | 2018-02-26 |
KR20120116400A (ko) | 2012-10-22 |
MY182750A (en) | 2021-02-05 |
JP6139885B2 (ja) | 2017-05-31 |
BR112012009846B1 (pt) | 2021-04-20 |
EP2494356A1 (en) | 2012-09-05 |
ZA201202999B (en) | 2013-06-26 |
IL219337A (en) | 2017-06-29 |
CA2778810A1 (en) | 2011-05-12 |
CA2778810C (en) | 2018-09-04 |
BR112012009846B8 (pt) | 2021-05-25 |
HK1175538A1 (zh) | 2013-07-05 |
WO2011056606A1 (en) | 2011-05-12 |
AU2010315470B2 (en) | 2016-05-05 |
MX344935B (es) | 2017-01-11 |
CN102695956A (zh) | 2012-09-26 |
DK2494356T3 (en) | 2017-05-15 |
US20110183363A1 (en) | 2011-07-28 |
EP2494356B1 (en) | 2017-03-15 |
MX2012004833A (es) | 2012-07-04 |
US9315583B2 (en) | 2016-04-19 |
AU2010315470A1 (en) | 2012-05-24 |
CN102695956B (zh) | 2015-12-09 |
NZ599600A (en) | 2015-04-24 |
RU2012121559A (ru) | 2013-12-10 |
SI2494356T1 (sl) | 2017-07-31 |
JP2013508740A (ja) | 2013-03-07 |
EP2494356A4 (en) | 2013-07-03 |
RU2642295C2 (ru) | 2018-01-24 |
IL219337A0 (en) | 2012-06-28 |
WO2011056606A8 (en) | 2012-05-18 |
HUE033492T2 (en) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012009846A2 (pt) | ensaios para detecção de anticorpos específicos para anticorpos anti-ige terapêuticos e seu uso em anafilaxia | |
WO2010065568A3 (en) | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 | |
BRPI0923199B8 (pt) | método para determinar a presença de anticorpos de fixação de complemento | |
BRPI1013179A2 (pt) | peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado | |
ATE550354T1 (de) | Humane ringspezifische bnp-antikörper | |
BRPI0818877A2 (pt) | Método e sistema para análise semi-quantitativa ou quantitativa de ensaios | |
DE602007012439D1 (de) | Homogener doppelrezeptor-agglutinationstest für immunsuppressiva | |
BR112016002685A2 (pt) | ensaios para timp2 que apresentam melhor desempenho em amostras biológicas | |
BR112016010106A2 (pt) | ensaios para igfbp7 com melhor desempenho em amostras biológicas | |
BR112012017014A8 (pt) | métodos para detecção de anticorpos de vírus jc | |
MY172290A (en) | Immunochromatography devices, methods, and, kits | |
RS54249B1 (en) | PROCEDURE FOR DETECTION OF ANTI-MEDICINAL ANTIBODIES | |
BR112012019475A2 (pt) | "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra | |
BRPI0721871A2 (pt) | Imunoensaios de alta sensibilidade e kits para a determinação de peptídeos e proteínas de interesse biológico | |
MX2009012048A (es) | Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato. | |
WO2012021741A3 (en) | Lateral flow assays for non-diagnostic analytes | |
WO2008136510A1 (ja) | 自己免疫性膵炎及び劇症1型糖尿病の検査方法及び検査試薬 | |
CY1113013T1 (el) | Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων | |
WO2010053772A3 (en) | Disease-associated antigens and methods of use thereof | |
DK1991875T3 (da) | Test til påvisning af patologiske prioner | |
GB202101700D0 (en) | Antibody detection assay | |
GB202014047D0 (en) | Sars-cov-2 antibody detection assay | |
GB202011047D0 (en) | Sars-cov-2 antibody detection assay | |
GB0501564D0 (en) | Test for prion disease | |
BR112013013762A2 (pt) | anticorpo monoclonal anti-cofilina 1 ou um fragmento do mesmo, imunoensaio da proteína cofilina 1, método para determinar se o câncer gastrointestinal está se desenvolvendo ou não e kit para quantificação de proteína cofilina 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |